Orkambi: Ph III data

Top-line data from a double-blind, international Phase III trial in 204 CF patients ages 6-11 with 2 copies of the F508 del mutation in the CFTR gene showed that twice-daily 250/200 mg

Read the full 328 word article

User Sign In